CME/CE
Jointly provided by Partners for Advancing Clinical Education (Partners) and DKBmed, LLC.
Acknowledgement
This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.
Target Audience
The intended audience for these five live presentations and enduring webinar will be all members of the community oncology care team including medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other HCPs involved in the care of patients with SCLC.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Assess efficacy and survival data from recent clinical trials supporting the use of new therapies and new therapeutic combinations in patients with ES-SCLC.
- Design strategies to monitor for and manage adverse events associated with novel combination regimens and new and emerging therapies in ES-SCLC.
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty / Presenter Reported Financial Relationship
| Faculty | Conflicts of Interest |
| Dr. Stephen Liu | Consultant, Advisor, Speaker: Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech/Roche, Gilead, GSK, Guardant Health, Johnson & Johnson, Jazz Pharmaceuticals, Merck, Merus, Natera, Novartis, Nuvalent, OSE Immunotherapeutics, Pfizer, PharmaMar, Regeneron, Revolution Medicines, SystImmune, Takeda, Yuhan Researcher: Abbvie, Alkermes, AstraZeneca, Avenzo, BioNTech, Bristol-Myers Squibb, Cogent Biosciences, Duality, Ellipses, Genentech, Gilead, Medilink, Merck, Merus, Nuvalent, OSE Immunotherapeutics, Puma, Synthekine, SystImmune |
| Dr. Jeffrey P. Ward | Consultant, Advisor, Speaker | Novocure, Obsidian Therapeutics, Astra Zeneca, Johnson and Johnson
Researcher | Genmab A/S, Instil Bio, Astra Zeneca Other | Pfizer, (spouse is an employee, Dr. Ward has no personal relationship with Pfizer) |
| Dr. Sonam Puri | Consultant, Advisor, Speaker: BMS, Novocure, Oncohost, Takeda, Janseen, Daiichi Sanko Inc, Amgen, AstraZeneca, Boerhringer Ingelheim |
| Dr. Mariam Alexander | Consultant, Advisor, Speaker -- Abbvie, Amgen, Daiichi Sankyo, Janssen, Regeneron |
| Dr. Misty Shields | Consultant, Advisor, Speaker: AstraZeneca |
| Dr. Wade Iams | Consultant, Advisor, Speaker --Amgen, Abbvie, Jazz Pharma, NovoCure, Nuvation Bio, AstraZeneca, Regeneron, Daiichi Sankyo |
| Dr. Eric Singhi | Consultant, Advisor, Speaker - Astra Zeneca, Novocure, Amgen, Janssen, Regeneron, BMS, Bayer, Lilly, BI, CARIS, Abbvie, GSK, Roche, Sandoz, Nuvation Bio, Nuvalent |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Partners designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.25 contact hours.
The maximum number of hours awarded for this enduring Nursing Continuing Professional Development activity is 1.00 contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 3/9/27. PAs should only claim credit commensurate with the extent of their participation.
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for enduring activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 3/9/27 PAs should only claim credit commensurate with the extent of their participation.
Pharmacist Continuing Education
Partners designates this continuing education activity for 1 contact hour(s) (1.25 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Numbers: Live Program: JA4008073-9999-26-003-L01-P
Enduring Program: JA4008073-9999-26-004-H01-P
Type of Activity: Knowledge
For Pharmacists (for live activities): Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.
For Pharmacists (for enduring activities): Upon successfully completing the post-test with a score of 75% or better (if applicable) and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating and receiving CME/CE credit for this activity.
Request for Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
Live Program
- Release date: January 28, 2026
- Expiration date: March 8, 2027
Enduring Program
- Release date: March 10, 2026
- Expiration date: March 9, 2027
Estimated time to complete the activity: 75 minutes
Hardware & Software Requirements
To access activities, users will need:
- A computer with an internet connection
- An HTML5 compliant web browser or Internet Explorer 8 (and higher)
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com